Fuan Pharmaceutical (Group) Co., Ltd. (SHE:300194)
China flag China · Delayed Price · Currency is CNY
3.530
-0.070 (-1.94%)
Nov 13, 2026, 3:04 PM CST

SHE:300194 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
1,5871,6782,3082,5712,3782,388
Other Revenue
60.1760.1783.176.9444.2264.71
1,6481,7382,3912,6482,4222,453
Revenue Growth
-3.74%-27.31%-9.68%9.33%-1.28%3.58%
Cost of Revenue
1,0381,1311,1741,2811,066935.97
Gross Profit
609.97607.611,2181,3671,3551,517
Selling, General & Admin
370.72400.6804.891,0211,0921,217
Research & Development
102.67134.66153.22148.79142.89120.38
Other Operating Expenses
33.929.386.915.3116.2828.08
Operating Expenses
508.52550.92968.971,1821,2551,370
Operating Income
101.4556.69248.55184.51100.24147.59
Interest Expense
-16.06-22.15-23.34-29.57-26.94-20.45
Interest & Investment Income
66.43168.16106.8109.4190.0774.46
Currency Exchange Gain (Loss)
0.20.20.980.661.47-0.59
Other Non Operating Income (Expenses)
-1.52-0.66-0.45-0.85-1.4-1.76
EBT Excluding Unusual Items
150.51202.23332.54264.17163.44199.26
Impairment of Goodwill
-129.02-129.02--224.51-22.97-201.06
Gain (Loss) on Sale of Investments
-1.83-1.86-32.740.410.420.75
Gain (Loss) on Sale of Assets
-1.510.270.01220.654.850.31
Asset Writedown
0.01-2.65-4.92-3.61-2.44-626.17
Other Unusual Items
33.2814.2817.333.2446.0734.93
Pretax Income
51.4483.24312.2290.36189.35-591.99
Income Tax Expense
17.216.7634.0355.95-11.4717.61
Earnings From Continuing Operations
34.2376.49278.17234.41200.82-609.59
Minority Interest in Earnings
0.510.511.67-2.543.79312.68
Net Income
34.7577279.84231.87204.61-296.91
Net Income to Common
34.7577279.84231.87204.61-296.91
Net Income Growth
-75.95%-72.48%20.69%13.32%--
Shares Outstanding (Basic)
1,3231,2831,1661,2201,2041,188
Shares Outstanding (Diluted)
1,3231,2831,1661,2201,2041,188
Shares Change
14.83%10.06%-4.46%1.40%1.34%2.10%
EPS (Basic)
0.030.060.240.190.17-0.25
EPS (Diluted)
0.030.060.240.190.17-0.25
EPS Growth
-79.06%-75.00%26.32%11.77%--

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
274.15203.8961.8113.3-43.6-155.91
Free Cash Flow Per Share
0.210.160.050.09-0.04-0.13
Dividend Per Share
0.0500.0700.0500.0500.050-
Dividend Growth
-28.57%40.00%0%0%0%-
Gross Margin
37.02%34.96%50.91%51.63%55.97%61.85%
Operating Margin
6.16%3.26%10.39%6.97%4.14%6.02%
Profit Margin
2.11%4.43%11.70%8.76%8.45%-12.10%
Free Cash Flow Margin
16.64%11.73%2.58%4.28%-1.80%-6.35%
EBITDA
310.11260.54446.01392.88284.11321.89
EBITDA Margin
18.82%14.99%18.65%14.84%11.73%13.12%
D&A For EBITDA
208.66203.86197.45208.37183.87174.29
EBIT
101.4556.69248.55184.51100.24147.59
EBIT Margin
6.16%3.26%10.39%6.97%4.14%6.02%
Effective Tax Rate
33.45%8.12%10.90%19.27%--
Revenue as Reported
1,6481,7382,3912,6482,4222,453
Advertising Expenses
-18.8924.052.440.480.5